HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) (NCT06634420)

🧪 Interventions in This Study

• NTLA-2002 (BIOLOGICAL)
• Normal Saline IV Administration (BIOLOGICAL)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (29 Sites)

Showing the first 25 of 29 sites.

• Medical Research of Arizona — Scottsdale, Arizona
• University of California, San Diego (UCSD) — San Diego, California
• Raffi Tachdjian MD, Inc — Santa Monica, California
• Allergy & Asthma Clinical Research — Walnut Creek, California
• IMMUNOe International Research Centers — Centennial, Colorado
• Asthma & Allergy Associates — Colorado Springs, Colorado
• University of South Florida — Tampa, Florida
• Massachusetts General Hospital — Boston, Massachusetts
• Washington University in St. Louis — St Louis, Missouri
• NYU Langone Health - Long Island — Mineola, New York
• Icahn School of Medicine at Mount Sinai — New York, New York
• Bernstein Clinical Research Center, LLC — Cincinnati, Ohio
• Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania
• AARA Research Center — Dallas, Texas
• Campbelltown Hospital — Campbelltown, New South Wales
• The Alfred Hospital — Melbourne, Victoria
• Royal Melbourne Hospital — Parkville, Victoria
• University of Alberta — Edmonton, Alberta
• Ottawa Allergy Research Corporation — Ottawa, Ontario
• CHU Grenoble-Alpes - Hopital Michallon — Grenoble,
• CHU de Lille - Hopital Claude Huriez — Lille,
• AP-HM - Hopital de la Timone — Marseille,
• Charite Universitaetsmedizin Berlin — Berlin,
• Universitaetsklinikum Frankfurt - Klinikum der Johann Wolfgang Goethe Universitaet — Frankfurt,
• Medizinische Hochschule Hannover (MHH) — Hanover,

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Hereditary Angioedema

• A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema — Birmingham, Alabama
• A Study to Assess the Long-Term Safety and Efficacy of Donidalorsen in the Prophylactic Treatment of Hereditary Angioedema (HAE) — Paradise Valley, Arizona
• A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema — Birmingham, Alabama
• Berotralstat Treatment in Children With Hereditary Angioedema — Vienna, Ontario
• Safety and Effectiveness of Sebetralstat (KVD900) for Short-Term Prophylaxis Before Procedures in People With Hereditary Angioedema (KONTROL) — Colorado Springs, Colorado

Explore by condition: All Hereditary Angioedema clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.